What happened
Seoul Pharma reported separate results for FY2025: revenue of US$35.5M (−2.5% year on year), an operating loss of US$823K (from a profit a year earlier) and net income of US$564K (−51.1% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$35.5M |
|---|---|
| Revenue vs a year earlier | −2.5% |
| Operating profit | −US$823K |
| Net income | US$564K |
| Period | FY2025 (separate) |
| Filed | 2026-02-06, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260206902089 → open original filing |
Source: DART. Information only, not investment advice.